Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinlarebant 3-year extension study in Stargardt disease
NL-OMON61035Phase 3Not yet recruiting
- Sponsor
- Belite Bio, Inc
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tinlarebant in Fundus Flavimaculatus (FF), sponsored by Belite Bio, Inc. Primary endpoints: Change in definitely decreased autofluorescence, Change in questionably decreased autofluorescence and 2 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tinlarebant
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on NL-OMON61035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61035.